Telmisartan is an oral specific non-peptide angiotensin II receptor (AT1 type) antagonist. It selectively binds to the AT1 receptor site with high affinity, persistently antagonizes angiotensin II, and causes a decrease in blood aldosterone levels, thereby lowering blood pressure. Telmisartan does not inhibit human plasma renin, nor does it block ion channels, nor does it inhibit angiotensin converting enzyme (kinase II), nor does it affect the degradation of bradykinin by the enzyme, so there will be no adverse reactions caused by the enhanced effect of bradykinin. For patients with hypertension, telmisartan can reduce systolic and diastolic blood pressure without affecting heart rate. No rebound hypertension occurs after discontinuation of telmisartan.

After oral administration, it can form a protective film on the gastric mucosa and stimulate the gastric mucosal epithelial cells to secrete mucus, increasing the protective effect on the mucosa. In addition, it can kill Helicobacter pylori and promote the healing of gastritis.

This product is rarely absorbed after oral administration and acts directly on the large intestine, stimulating its sensory nerve endings, causing increased rectal reflex peristalsis and leading to defecation.